Emerging Molecular Technologies in Genitourinary Tumors

Giunchi, Francesca; Cimadamore, Alessia; Fiorentino, Michelangelo

doi:10.3389/fonc.2018.00489

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24] Detailed reviews on the roles of oncometabolites in mitochondrial dysfunction, [25] such as d-2-hydroxyglutarate, l-2-hydroxyglutarate, succinate, and fumarate, are available elsewhere. [26] Reviews have focused on providing the metabolic signatures of cancer, including the roles of oncometabolites and the basic pathways, the central role of serine metabolism in tumor growth, lipid metabolism's role in driving disease pathogenesis, linking tumor metabolism with the mutational landscape, and metabolic biomarkers for the prediction of breast cancer progression [27] and prostate cancer, [28] among others. A recent review focused on the metabolic signatures of cancer cells and on roles of S-adenosylmethionine and alpha-ketoglutarate; the review highlighted the role of glucose and glutamine as fundamental substrates for mammalian cell LC-MS/MS [116] Cystathionine Breast cancer It protected breast cancer cells against excess reactive oxygen species (ROS) and chemotherapeutic drug-induced apoptosis.…”

Section: Opportunities Beyond Warburg's Effect Glycolysis Lactate Mmentioning

confidence: 99%

Challenges and Opportunities in Cancer Metabolomics

Kumar

Misra

2019

Proteomics

View full text Add to dashboard Cite

Challenges in metabolomics for a given spectrum of disease are more or less comparable, ranging from the accurate measurement of metabolite abundance, compound annotation, identification of unknown constituents, and interpretation of untargeted and analysis of high throughput targeted metabolomics data leading to the identification of biomarkers. However, metabolomics approaches in cancer studies specifically suffer from several additional challenges and require robust ways to sample the cells and tissues in order to tackle the constantly evolving cancer landscape. These constraints include, but are not limited to, discriminating the signals from given cell types and those that are cancer specific, discerning signals that are systemic and confounded, cell culture‐based challenges associated with cell line identities and media standardizations, the need to look beyond Warburg effects, citrate cycle, lactate metabolism, and identifying and developing technologies to precisely and effectively sample and profile the heterogeneous tumor environment. This review article discusses some of the current and pertinent hurdles in cancer metabolomics studies. In addition, it addresses some of the most recent and exciting developments in metabolomics that may address some of these issues. The aim of this article is to update the oncometabolomics research community about the challenges and potential solutions to these issues.

show abstract